Nordimet® is indicated for the treatment of:1

  • - active rheumatoid arthritis in adult patients,
  • - polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,
  • - severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms of therapy such as phototherapy, psoralens and ultraviolet A (PUVA), and retinoids, and severe psoriatic arthritis in adult patients,
  • - induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.

Nordimet®: a range of indications and presentations

8 presentations, in 2.5mg increments from 7.5mg to 25mg

  • The dose should be reduced to the lowest possible
    effective maintenance dose, once the desired therapeutic
    result is achieved

  • The recommended initial dose is 7.5mg
    once weekly, administered subcutaneously

  1. Nordimet® Summary of Product Characteristics. Available at: